<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Infusion of <z:chebi fb="199" ids="26708">sodium</z:chebi> <z:chebi fb="95" ids="16301">nitrite</z:chebi> could provide sustained therapeutic concentrations of nitric <z:chebi fb="177" ids="25741,29356">oxide</z:chebi> (NO) for the treatment of a variety of <z:e sem="disease" ids="C0042373" disease_type="Disease or Syndrome" abbrv="">vascular disorders</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>The study was developed to determine the safety and feasibility of prolonged <z:chebi fb="199" ids="26708">sodium</z:chebi> <z:chebi fb="95" ids="16301">nitrite</z:chebi> infusion </plain></SENT>
<SENT sid="2" pm="."><plain>METHODOLOGY: Healthy volunteers, aged 21 to 60 years old, were candidates for the study performed at the National Institutes of Health (NIH; protocol 05-N-0075) between July 2007 and August 2008 </plain></SENT>
<SENT sid="3" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> subjects provided written consent to participate </plain></SENT>
<SENT sid="4" pm="."><plain>Twelve subjects (5 males, 7 females; mean age, 38.8±9.2 years (range, 21-56 years)) were intravenously infused with increasing doses of <z:chebi fb="199" ids="26708">sodium</z:chebi> <z:chebi fb="95" ids="16301">nitrite</z:chebi> for 48 hours (starting dose at 4.2 µg/kg/hr; maximal dose of 533.8 µg/kg/hr) </plain></SENT>
<SENT sid="5" pm="."><plain>Clinical, physiologic and laboratory data before, during and after infusion were analyzed </plain></SENT>
<SENT sid="6" pm="."><plain>FINDINGS: The maximal tolerated dose for intravenous infusion of <z:chebi fb="199" ids="26708">sodium</z:chebi> <z:chebi fb="95" ids="16301">nitrite</z:chebi> was 267 µg/kg/hr </plain></SENT>
<SENT sid="7" pm="."><plain>Dose limiting toxicity occurred at 446 µg/kg/hr </plain></SENT>
<SENT sid="8" pm="."><plain>Toxicity included a transient asymptomatic decrease of mean arterial blood pressure (more than 15 mmHg) and/or an asymptomatic increase of methemoglobin level above 5% </plain></SENT>
<SENT sid="9" pm="."><plain><z:chebi fb="95" ids="16301">Nitrite</z:chebi>, nitrate, S-nitrosothiols concentrations in plasma and whole blood increased in <z:hpo ids='HP_0000001'>all</z:hpo> subjects and returned to preinfusion baseline values within 12 hours after cessation of the infusion </plain></SENT>
<SENT sid="10" pm="."><plain>The mean half-life of <z:chebi fb="95" ids="16301">nitrite</z:chebi> estimated at maximal tolerated dose was 45.3 minutes for plasma and 51.4 minutes for whole blood </plain></SENT>
<SENT sid="11" pm="."><plain>CONCLUSION: <z:chebi fb="199" ids="26708">Sodium</z:chebi> <z:chebi fb="95" ids="16301">nitrite</z:chebi> can be safely infused intravenously at defined concentrations for prolonged intervals </plain></SENT>
<SENT sid="12" pm="."><plain>These results should be valuable for developing studies to investigate new NO treatment paradigms for a variety of clinical disorders, including <z:e sem="disease" ids="C0265110" disease_type="Disease or Syndrome" abbrv="">cerebral vasospasm</z:e> after <z:hpo ids='HP_0002138'>subarachnoid hemorrhage</z:hpo>, and <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> of the heart, liver, kidney and brain, as well as organ transplants, blood-brain barrier modulation and <z:hpo ids='HP_0002092'>pulmonary hypertension</z:hpo> </plain></SENT>
<SENT sid="13" pm="."><plain>CLINICAL TRIAL REGISTRATION INFORMATION: http://www.clinicaltrials.gov; NCT00103025 </plain></SENT>
</text></document>